Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro.
about
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the ClinicMesenchymal stem cells in pathogenesis of myelodysplastic syndromesMyelodysplasia is in the niche: novel concepts and emerging therapies.Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.Ex vivo identification and characterization of a population of CD13(high) CD105(+) CD45(-) mesenchymal stem cells in human bone marrow.Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patientsDown-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.No telomere shortening in marrow stroma from patients with MDS.Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Mesenchymal stem cells in immune-mediated bone marrow failure syndromes.The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression.Myeloid malignancies and the microenvironment.Mesenchymal stromal cells in myeloid malignancies.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS.Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gammaBiological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemiaCytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders.Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.Bone marrow mesenchymal stem cells in myelodysplastic syndromes: cytogenetic characterization.Role of the microenvironment in myeloid malignancies.Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes.Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.Phenotypic and Cytogenetic Characterization of Mesenchymal Stromal Cells in De Novo Myelodysplastic Syndromes.
P2860
Q26746104-DA71F8FF-D576-4E3D-9FCA-743C0F9D9BC1Q26752778-D984536C-A65C-4BB4-B55D-6FC2F55B8F77Q27011323-F182D6FB-1657-46E9-A1FD-21C3BD096335Q35059425-76D95D85-BD3F-4FA2-9BF1-0B9FC6F9136AQ35553350-58C5BADA-E071-4F95-BA25-4ADA396AEB15Q36034814-49113973-3B3F-48EF-9254-2F4A8B84793CQ36133030-BBB87438-9E80-4BAA-848E-488271B3E1B3Q36715982-2FAE512D-06AC-4B28-9077-C363D6C90F97Q37219621-98739733-71FA-434C-A74D-9B7D4A895533Q37273157-9D2C3CE6-4F1F-4341-BA3F-D82058B4C820Q37830375-7406391B-1A77-46BC-9743-826DA0911D16Q37864686-6A2655D1-08E3-495E-850F-BC80695EBA97Q38175397-9782F2BB-567C-4F70-9F57-2E49E1E6AB26Q38615755-A4947806-5E06-4469-8498-4E7BA098577CQ39073878-8DA043CE-5BCC-4689-938A-11AE851DA629Q39090002-A99311EB-0DBB-4B91-91D0-1FAF8BC73A66Q39155501-D48FE80E-6446-4438-840C-3BDC6B4315F3Q41968172-52FC278D-E85F-4127-AD36-70CBD6C5F4CFQ42193815-F75A76EE-ED99-44C9-AA47-2C543CC50BFDQ42263167-21BC9683-19EA-4F4D-B586-142426C85440Q43984170-0F5DAC3D-5BB7-4801-B561-2CDE5C830A96Q44998014-C5B7AC73-EB41-4572-B3FF-995DA48CF52BQ46155958-99B5FDE8-DB2D-4836-983D-E95AE2BA5D8CQ49986947-AB255346-11F8-4CA0-8318-F7C824646588Q50480672-EBFBB2E3-B36D-4577-A905-816B6425ABE5Q50904123-B1963A0F-7BB8-45AA-BB62-F58E78A0F857Q53023244-4B9A88C9-C149-4E96-9E73-66D57D2EDB55
P2860
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Mesenchymal cells generated fr ...... g-term hematopoiesis in vitro.
@en
type
label
Mesenchymal cells generated fr ...... g-term hematopoiesis in vitro.
@en
prefLabel
Mesenchymal cells generated fr ...... g-term hematopoiesis in vitro.
@en
P2093
P2860
P356
P1433
P1476
Mesenchymal cells generated fr ...... ng-term hematopoiesis in vitro
@en
P2093
Alain Bernheim
Cristina Tourino
Jean-Henri Bourhis
Marie-Laure Bonnet
Martine Guillier
Pierre Fenaux
Stéphane Flamant
Valérie Soenen-Cornu
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208405
P407
P577
2005-04-01T00:00:00Z
P5875
P6179
1035936742